Scleroderma Registry & Repository at the Hospital for Special Surgery
Purpose
The overall objective of the Scleroderma Registry is to support and promote the basic science and clinical research of this complex rheumatic disease at the Hospital for Special Surgery (HSS). The registry facilitates our understanding of the clinical features, pathobiology, genetics of Scleroderma. This will ultimately lead to a potential treatment for this currently untreatable condition.
Condition
- Scleroderma
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Individuals older than 18 years of age with Scleroderma
Exclusion Criteria
- Individuals younger than 18 years of age - Individuals older than 18 years of age without Scleroderma
Study Design
- Phase
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
| Patients with Scleroderma | Patients who have been diagnosed at any point in their life with Scleroderma will compose the cohort. |
Recruiting Locations
New York 5128581, New York 5128638 10021
More Details
- Status
- Recruiting
- Sponsor
- Hospital for Special Surgery, New York
Detailed Description
What will be asked of you: - Completion of 2 health questionnaires - Donation of research bloods. This is optional, but encouraged (if possible). - We also encourage patients who come for initial visits to return so follow-up data can be collected. Benefits to Patients: - The HSS Scleroderma Registry gives patients the opportunity to participate in observational research with the goal of improving the lives of patients in the future. - By donating research bloods and providing clinical information, patients will help generate new knowledge about Scleroderma that can guide the treatment and care of patients afflicted with this rare disease. - Patients will also receive a comprehensive, medical evaluation from an HSS physician who specializes in treating Scleroderma. He or she will provide guidance on treatment options and recommendations for current or upcoming clinical trials. - Physicians will also make patients aware of the resources available to them, including support groups and educational programs.